Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node–negative breast carcinoma: prognostic relevance☆

摘要: In patients with lymph node-negative breast carcinoma (LNNBC), the prevalence of HER2 overexpression and gene amplification their prognostic value have not been extensively evaluated. We examined 162 LNNBC complete follow-up. Immunohistochemistry (IHC) for HER2, Ki67, p53 was performed. status analyzed by chromogenic in situ hybridization (CISH) discordant cases fluorescence hybridization. seen 24.7% (40/162) CISH 17.6% (28/159). Agreement between IHC achieved 147 (92.5%) cases. Amplification 21 (100%) (3+), 6 (35.3%) 17 (2+), 1 (0.6%) 121 (0-1+) tumors. Fluorescence detected 3 (1.8%) additional were present tumors high grade, necrosis lymph-vascular invasion (LVI) (all P < .027). addition, amplified showed Ki67 more than 20% (P .05). By univariate analysis, shorter disease-free survival (DFS) overall (OS) showing amplification, LVI, .05) (Kaplan-Meier). However, multivariate analysis (Cox regression) demonstrated only as an independent factor both DFS = .017) OS .010), a trend (OS, .087) LVI (DFS, .11; OS, .063). conclude that is reliable method detecting expression can be complemented nondefinitive (2+). Moreover, valuable tool assessment potential and, therefore, clinical decision making treatment high-risk LNNBC.